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Abstract
Studies on immunological reconstitution after immune ablation and stem-cell therapy may
yield important clues to our understanding of the pathogenesis of human autoimmune
disease, due to the profound effects of function and organization of the immune system.
Such studies are also indispensable when linking clinical sequelae such as opportunistic
infections to the state of immune deficiency that ensues after the treatment. Much has been
learnt on these issues from comparable studies in haemato-oncological diseases, although it
remains to be proven that the data obtained from these studies can be extrapolated to
rheumatological autoimmune diseases. Preliminary results from pilot studies in various
rheumatological conditions not only pointed to clinical efficacy of the new treatment modality
but also unveiled marked effects on T-cell receptor repertoires of circulating T lymphocytes,
on titres of autoantibodies and T- and B-cell subsets.
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Introduction
The emergence of high-dose immunosuppressive therapy
(HDIT), followed by autologous haematopoietic stem-cell
transplantation (SCT) as a new treatment modality for
selected patients with systemic rheumatic diseases is
based on a pivotal role of the immune system in the
course of such diseases [1•]. The aim is to maximally sup-
press or ablate the immune system and then rescue the
patient from prolonged cytopenias or haematopoietic
failure by infusing haematopoietic progenitor cells
(CD34+ cells). Studies in experimental models of autoim-
mune disease in particular have lent support to the
concept that autoreactive T lymphocytes can be elimi-
nated by (myelo)lymphoablative chemo(radio)therapy, and
that the subsequent transplantation of pluripotent
haematopoietic stem cells gives rise to the emergence of
naïve T lymphocytes that are tolerant to self-antigens
(reviewed in this issue by van Bekkum [2]).
In humans, the pathogenesis of systemic rheumatic dis-
eases is less well understood due to uncertainties regarding
the nature of autoantigens, pathogenic roles of specific T
and B lymphocytes, and complexity of cell–cell interactions.
Study of the reconstituting immune system in relation to the
disease course after HDIT and SCT may, however, yield
important insights into the pathogenesis of these diseases
because of the temporary profound effects of myeloablative
or lymphoablative therapy on the immune system. This holds
true for autologous SCT in particular, because it entails
neither histoincompatibility (with its attendant risk for graft-
versus-host disease) nor the use of immunosuppressive
drugs to control such histoincompatibility.http://arthritis-research.com/content/2/4/270
Clinical considerations also stress the need to incorporate
monitoring of immune reconstitution in any treatment proto-
col. It is well appreciated that the risks associated with
HDIT and SCT in terms of morbidity and mortality are deter-
mined by numerical recovery of bone marrow cellular ele-
ments on the one hand, and functional recovery of cellular
interactions on the other. These surrogate parameters of
immunological reconstitution in turn depend on the treat-
ment protocol employed. Current trials involve regimens that
range from HDIT (eg cyclophosphamide) alone to
(myelo)lymphoablative conditioning, in combination with
SCT and vigorous T-cell depletion [3•]. It can be anticipated
that the more intensive the treatment is, the higher the risks,
because of a temporary lack of functional T lymphocytes
after treatment. Regeneration of adequate T-cell numbers
and repertoire diversity is a key element in the recovery of
immune competence. In the absence of such recovery, sus-
ceptibility to opportunistic infections is increased.
The present review focuses on reconstitution of the
various components of the immune system after HDIT and
SCT, with emphasis on the determinants of immune
reconstitution (Table 1). Special attention is paid to recon-
stitution of CD4+ T lymphocytes, which are considered to
be key players in many autoimmune diseases [4].
To date only scarce data on immune reconstitution exist in
patients with rheumatic disease, most of whom have been
treated with (myelo)lymphoablative chemo(radio)therapy
and autologous SCT obtained by mobilization of periph-
eral blood stem cells. In contrast, many data have been
gathered in patients with haematological or oncological
disease treated with HDIT alone or HDIT followed by
either autologous or allogeneic SCT. These studies
involved different diseases and heterogeneous treatment
protocols with regard to source of stem cells (blood
versus bone marrow), and mobilization and conditioning
regimens. Thus, the data generated in these studies
should be interpreted with the understanding that the
overall effect of a treatment protocol on immune reconsti-
tution is the sum of various interventions. However, some
basic principles seem to govern reconstitution of the
immune system after HDIT (with or without SCT), most
notably pertaining to T and B lymphocytes [5••].
T- and B-lymphocyte reconstitution
Theoretically, the T-lymphocyte population after HDIT and
SCT can be regenerated with T lymphocytes from four
sources: from expansion of T cells that are reinfused along
with the stem cells; from transfused or residual stem cells
through a process of thymic education, comparable to
what happens in early childhood; from stem cells through
an extrathymic pathway; and from residual memory T cells
that survive the conditioning regimen.
Obviously, in case of HDIT alone, reconstituting T lympho-
cytes can only be derived from either endogenous stem
cells or mature T lymphocytes that have survived the treat-
ment. Age (which is associated with diminished thy-
mopoiesis) and the extent of T-cell depletion (by in vivo or
ex vivo manipulation of the graft or by [myelo]lymphoabla-
tion) are the major determinants of the relative contribu-
tions of these sources to the recovery of T-lymphocyte
population after HDIT and SCT [5••]. This is reflected
mainly in the CD4+ lymphocyte compartment, as assessed
by immunophenotyping of circulating T cells. Naïve CD4+
T lymphocytes bear the CD45RA isoform, whereas
memory CD4+ T lymphocytes express the CD45RO
isoform. The level of naïve (CD45RA+) CD4+ cells drops
rapidly after HDIT (whether followed by SCT or not) and
recovers slowly, whereas levels of memory (CD45RO+)
CD4+ and CD8+ cells recover more rapidly, and some-
times even ‘overshoot’ [6•,7,8•]. As a result, a prolonged
T-cell subset imbalance with inverted CD4:CD8 ratios is
found that can last for longer than a year, depending on
the protocol.
These differential effects are explained by differences in
maturation pathways for T-cell subsets. In principle, recon-
stitution of the naïve T-cell compartment is achieved by
thymus-dependent and thymus-independent pathways.
The development of naïve CD4+ T lymphocytes from stem
cells has been shown to be mainly thymus dependent. The
observation of an inverse correlation between the size of
the thymus and the level of the CD4+ cells in the periph-
eral blood after HDIT (without SCT) supports the notion
that CD4+ development depends on residual thymus func-
tion [9•]. Additional evidence was recently obtained by
T-cell receptor (TCR) recombination excision circle analy-
sis [10•], which showed that thymic output of immature
naïve CD4+ T lymphocytes decreases rapidly early in life,
and stabilizes at a low level after adolescence and until old
age. In contrast, levels of circulating memory CD4+ T lym-
Table 1
Determinants of immune reconstitution after HDIT and SCT
Age-dependent thymopoiesis in children versus adults [5••,6•,7,9•,10•,11]
Source of hematopoietic stem cells:
allogeneic versus autologous [8•];
bone marrow versus peripheral blood [8•,13,41•,42]
Mobilization protocol: G-CSF alone versus chemotherapy and G-CSF [42]
Conditioning regimen: myeloablative versus intensive 
immunosuppressive [5••]
Manipulation of graft (ex vivo T-cell depletion or CD34 enrichment) 
versus in vivo T-cell depletion versus nonmanipulation of graft 
[5••,16••,17•,18•,19,20••]
Pre- and post-transplant treatment? [43]
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phocytes and of CD8+ T lymphocytes are not severely
affected by HDIT and SCT. This is because thymus-inde-
pendent maturation pathways dictate the regeneration of
CD8+ T lymphocytes comprising both extrathymic lym-
phopoiesis from haematopoietic precursors and peripheral
expansion of mature CD8+ T cells, especially the
CD8+CD28– subset [6•].
Cotransfused or residual memory CD4+ T cells also
expand during the first months after transplantation
[11,12•]. The peripheral expansion of mature T lympho-
cytes observed after HDIT (with or without SCT) has been
attributed in part to the encounters with viruses, and is
reflected by the elevated expression of activation markers
CD25, CD38 and most notably human leucocyte
antigen-DR [13,14]. The wave of activated memory CD4+
T lymphocytes subsequently subsides due to increased
susceptibility to apoptosis [15•]. In the autologous trans-
plant setting it is difficult to determine the precise origin
(cotransfused or residual) of this early expanded T-cell
pool. Data from studies in recipients of T-cell-depleted
allogeneic bone marrow transplant (BMT) [11,12•,16••]
indicate that the early post-transplant T-cell compartment
has a mixed origin, with T cells derived from both trans-
ferred donor T cells and surviving host T cells. In contrast,
in patients who underwent unmanipulated BMT, only few
recipient T-cell clones were detected, and most were of
donor origin. It is likely that similar competing mechanisms
apply in the autologous setting. In keeping with this is the
observation that recovery of total numbers of circulating
CD4+ T lymphocytes after HDIT and SCT is related to the
number of T lymphocytes present in the graft. T-cell deple-
tion or CD34+ stem-cell enrichment of a graft leads to
delayed CD4 lymphocyte recovery, and CD4 lymphocyte
recovery occurs more rapidly after autologous peripheral
blood SCT than after autologous BMT because higher
numbers of lymphocytes in the former graft [13,16••,17•].
Whatever the origin of these early memory T cells, the initial
expansion of a limited number of mature T-cell clones
results in a skewed oligoclonal repertoire, whereas subse-
quent diversification of TCR repertoires after T-cell-depleted
SCT is dependent on the capacity of the thymus to gener-
ate naïve thymic emigrants [18•,19]. Molecular analysis of
TCR repertoires by CDR3 size spectratyping has revealed
differences in T-cell populations isolated before and after
transplantation with CD34+-enriched autologous peripheral
blood stem cells, possibly in response to antigenic stimuli or
to a stochastic process [20••].
Analogous to repopulating T lymphocytes, post-transplant
B lymphocytes are derived from either cotransfused or
residual B cells, or from transplanted or residual stem
cells, depending on the treatment regimen employed. The
documented transfer of humoral immunity in allogeneic
transplantation suggests that differentiated antigen-
selected B cells in the graft can be a significant contribu-
tor to post-transplant B cells, whereas residual B cells
have also been demonstrated to contribute [5••]. Finally,
immunophenotyping data lend support to a role of stem
cells as a source of post-transplant circulating B cells.
After an initial drop in circulating CD19+ and CD20+
mature B cells, B cells emerge with an undifferentiated
phenotype. In the case of CD34+-selected SCT, an over-
representation of CD5+CD19+ B cells can be detected
during the early post-transplant period, but the signifi-
cance of this is not well understood [20••]. Although the
regeneration of B cells after transplantation has been
interpreted as a recapitulation of foetal ontogeny, this has
been disputed on the basis of structural differences in
B-cell receptor repertoires [21].
Functional effects of immune ablation and
stem cell therapy
HDIT and SCT not only affects numbers and repertoires of
T and B lymphocytes, but induces functional changes as
well. Defective T-cell proliferative responses to mitogens,
and TCR-crosslinking antibodies may partly be caused by
high numbers of monocytes that are present in growth
factor-mobilized peripheral blood-derived SCT, or by type
2-associated cytokines [22–24]. Defective in vitro produc-
tion of IL-2, IL-10 and IFN-g, but not of IL-4, by peripheral
blood mononuclear cells during the first 6 months after
HDIT and SCT has also been demonstrated, although the
data on IL-10 are conflicting [25,26]. An early expansion
of a memory CD4+CD7– T-cell subset with preferential
IL-4 production has been detected after HDIT and SCT,
but not after HDIT alone [27]. The in vivo degree of T-cell
incompetence after HDIT and SCT is difficult to gauge
exactly  in vitro, however. Deficiences in humoral
responses after HDIT and SCT are attributed both to
decreased T-cell help and intrinsic B-cell defects.
Immunological monitoring in patients with
systemic rheumatic disease
Studies on immune reconstitution after HDIT (with or
without SCT) in patients suffering from severe rheumato-
logical conditions have only recently started to emerge
[28]. These conditions predominantly include rheumatoid
arthritis (RA), systemic lupus erythematosus, systemic
sclerosis and juvenile chronic arthritis. Different proto-
cols are being employed to treat these conditions,
varying from HDIT alone to (myelo)lymphoablation fol-
lowed by autologous SCT and in vivo T-cell depletion
with antithymocyte globulin or Campath (LeukoSite Inc,
Cambridge, MA, USA) monoclonal antibody or ex vivo
graft manipulation [3•].
The aim of graft manipulation is to minimize the risk of re-
infusing autoreactive T lymphocytes. To this end, the graft
is purged of T cells by monoclonal antibodies or enriched
for CD34+ stem cells. In the latter case, monocytes,natural killer cells and B cells are de facto depleted from
the graft also.
Obviously, different regimens will produce different results
on immune reconstitution. The data generated thus far
seem generally comparable to those obtained in haemato-
oncological diseases with respect to immunophenotyping
of circulating mononuclear cells. The bottom line is that
recovery of natural killer cells and monocytes after HDIT
and SCT is prompt, but that numerical and functional
recovery of lymphoid and immune effector cells occurs
more gradually.
In three RA patients, mobilization of haematopoietic stem
cells with HDIT and granulocyte colony-stimulating factor
(G-CSF) alone led to a drop in the number of circulating
CD45RA+ naïve T lymphocytes, whereas the number of
circulating memory cells was more stable [29]. transient
decrease in rheumatoid factor (RF) level was reported.
Interestingly, an increase in the level of circulating
CD4+CD7– T cells appeared to be associated with
disease relapse. This T-cell subset is suspected of playing
a role in the pathogenesis of RA [30]. It would be of inter-
est to assess the cytokine profile of this subset in these
patients, in the light of the above-mentioned preferential
IL-4 production of this subset in patients with haematolog-
ical diseases.
HDIT with unmanipulated SCT led to substantial clinical
responses in four RA patients, concomitant with moderate
depressions of RF levels in blood [31]. The persistence of
RF positivity cannot solely be explained by the putative
reinfusion of autoaggressive lymphocytes, because HDIT
without SCT had comparable effects [32].
In another study [33••], a patient with RA was treated with
a myeloablative conditioning regimen, followed by SCT
that was T-cell depleted and CD34+ enriched. Enumera-
tion by flow cytometry of CD4+ T cells expressing TCRs of
different Vb families showed a restoration of T-cell diver-
sity compared with the major skewing seen 3 months after
transplantation, but with differences in the relative contri-
butions of the families in pre- and post-transplant reper-
toires.  In vitro T-cell proliferative responsiveness and
delayed-type skin hypersensitivity to a recall antigen
returned to pretransplant levels.
A sustained clinical response was achieved in two out of
four RA patients treated with HDIT (cyclophosphamide),
antithymocyte globulin and positively selected SCT [34].
RF was only slightly reduced in three patients, but disap-
peared at 6 months in one of the responder patients. The
same treatment in two lupus patients led to an initial
decrease in antinuclear antibody titres and antidouble-
stranded DNA antibodies, concomitant with a clinical
response. In a girl with systemic sclerosis a marked and
sustained improvement in skin score and general well-
being was observed 2 years after the transplantation pro-
cedure [35]. No correlation was found with the results of
in vitro proliferation tests and immunophenotyping of cir-
culating mononuclear cells. The persistence of autoanti-
bodies (antinuclear and anti-Scl70) suggested that not all
autoimmune clones were eradicated.
Conclusion
The present data do not allow firm conclusions to be
drawn regarding the correlation of clinical responses and
results of immunological monitoring. At this point it must
be recalled that, in RA patients, therapies with anti-CD4
monoclonal antibodies were not very effective, despite
prolonged depletion of circulating CD4+ T lymphocytes
[36]. As a possible mechanism it was shown [37] that
IFN-g producing memory CD4+ T lymphocytes were
spared by this treatment and that CD4+ T lymphocytes
persist in the joints. Other studies in RA [38] have also
demonstrated lack of correlation between numbers of cir-
culating cells and clinical responses, with persistence of
synovial mononuclear cell infiltrates.
From a critic’s viewpoint, eradication of autoreactive
memory T and B lymphocytes by autologous SCT may be
impossible, and allogeneic SCT may be necessary to
achieve this goal. A cure may also remain elusive if
rheumatic diseases originate in stem-cell defects, as has
been mooted for RA and systemic lupus erythematosus
[39]. Optimists are supported by the beneficial clinical
effects observed thus far. In any case, an extensive search
for mechanisms that underlie the remissions observed in
many patients, and the relapses that occurred in others
seems justified. Whether these mechanisms turn out to be
only related to rigorous modulation of the immune system,
or whether effects on nonimmune cells are also involved
needs to be investigated [40]. It is up to the rheumatolo-
gists and immunologists to proceed by close collabora-
tion, preferentially across institutional and national
borders, to address the fundamental questions associated
with this new treatment modality.
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